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Long-lived plasma cells (PCs) contribute to humoral immunity through an undeﬁned mechanism.
Memory B cells, but not human naïve B cells, can be induced to differentiate into long-lived PCs
in vitro. Because evidence links a proliferation-inducing ligand (APRIL), a tumor necrosis factor family
member, to the ability of bone marrow to mediate long-term PC survival, we reasoned that APRIL inﬂu-
ences the proliferation and differentiation of naïve B cells. We describe here the development of a simple
cell culture system that allowed us to show that APRIL sustained the proliferation of naïve human B cells
and induced them to differentiate into long-lived PCs. Blocking the transmembrane activator and calcium
modulator and cyclophilin ligand interactor or B-cell mature antigen shows they were required for the
differentiation of naïve B cells into long-lived PCs in vitro. Our in vitro culture system will reveal new
insights into the biology of long-lived PCs.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A proliferation-inducing ligand (APRIL) is a member of the
tumor necrosis factor (TNF) family of cytokines that regulate the
growth, maturation, differentiation, and survival of B cells [1–4].
APRIL signaling through its receptors, which are the members of
the TNF receptor family, B-cell maturation antigen (BCMA), and
transmembrane activator and calcium modulator and cyclophilinligand interactor (TACI), mediates the late stage of B cell develop-
ment [5–11]. In a mouse model, APRIL deﬁciency decreases the
ability of the bone marrow to support plasma cell (PC) survival
[12]. APRIL is secreted by neutrophils, macrophages, and bone-
marrow stromal cells in vivo, and lipopolysaccharide or inter-
feron-c induces dendritic cells to produce APRIL in vitro. These
ﬁndings suggest that APRIL may be related to inﬂammation and
innate immunity. Indeed, APRIL is implicated in autoimmune dis-
orders, particularly systemic lupus erythematosus (SLE) and
Sjogren’s syndrome (SS). For example, the serum levels of APRIL
in patients with SLE and SS are elevated compared with those of
healthy controls [13–16].
APRIL plays an important role in the survival of PCs in mice, but
its contributions to human B cell development are yet to be fully
deﬁned, particularly during PC differentiation. In vitro culture sys-
tems have been reported in which human B cells are activated to
drive the PC phenotype [17,18]. For example, Ettinger et al.
[19–21] reported that IL-21 could induce human naïve and mem-
ory B cells to acquire a PC phenotype following stimulation
through BCR and CD40. Such PCs express the surface markers
IgDCD38++ and BCMA+, although it is unclear if they are involved
with CD138 (syndecan-1) expression, which is a speciﬁc marker for
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Unmethylated CpG-oligodeoxynucleotides (ODNs) induce dif-
ferentiation of memory B cells to PCs in the absence of BCR
stimulation [23]. Huggins et al. [23] demonstrated that naïve B
cells can differentiate into PCs after addition of a CpG-ODN,
CD40L, IL-2, IL-6, IL-10, IL-15, and hepatocyte growth factor
(HGF) in a three-step culture system, and that the induced PCs
express CD138. Cytokines such as IL-6, insulin-like growth factor-
1, and HGF are secreted by bone-marrow stromal cells, and the
local environment in the bone marrow is thought to support the
survival of PCs [24]. Our group recently reported an immunosup-
pressive agent susceptibility for the differentiation of human B
(CD19+) cells in vitro that employs IL-21, CD40L, and CpG-ODNs.
This system induces IgG production but does not maintain the sur-
vival of PCs for a long period [25]. Therefore, in the present study,
we added APRIL to this in vitro culture system and show that APRIL
supports the differentiation of naïve B cells into PCs, which efﬁ-
ciently secrete IgG and almost no changes in proliferation.
Moreover, a receptor-blocking assay shows that APRIL via TACI
and BCMA plays an important role in the differentiation of human
naïve B cells to PCs in vitro.2. Materials and methods
2.1. Isolation and culture of B cells
This study followed the Declaration of Helsinki, and all subjects
provided informed consent for participation. Peripheral blood
mononuclear cells were isolated using a Ficoll–Hypaque density
gradient (Sigma–Aldrich, St. Louis, MO, USA) from 10 healthy
donors (ages 21–63 years; average, 37.6 ± 13.9 years; seven males).
To isolate memory B cells from naïve B cells, mononuclear cells
were subjected to negative selection using a B-cell isolation kit
(Miltenyi Biotech, Auburn, CA, USA). The unlabeled B cells were
passed through the column, washed with buffer, and subjected to
magnetic-activated cell sorting (MACS) using CD27-conjugated
microbeads according to the manufacturer’s instructions.
The cells were cultured in basal B-cell culture medium com-
posed of Iscove’s modiﬁed Dulbecco’s medium (Sigma–Aldrich)
containing 10% fetal calf serum (FCS; Thermo Scientiﬁc HyClone,
NYSE, TMO) supplemented with 50 lg/ml human transferrin–sele-
nium and 5 lg/ml human insulin (Gibco Invitrogen Co., Carlsbad,
CA, USA) in the presence of the molecules as follows: 50 ng/ml
IL-21, 2.5 lg/ml phosphorothioate CpG-ODN 2006, 50 ng/ml his-
tidine-tagged soluble recombinant human CD40L, and 5 lg/ml
anti-polyhistidine monoclonal antibody (mAb). We added TNF
family members to the naïve (CD27) B-cell culture medium as
follows: 500 ng/ml recombinant human APRIL or 50 ng/ml recom-
binant human B-cell-activating factor (BAFF). We used an anti-
human IgM afﬁnity-puriﬁed goat polyclonal Ab (4 lg/ml) to stimu-
late the BCR. Puriﬁed naïve (CD27) B cells were added to 96-well
ﬂat-bottom plates (1.6  104 cells per well).2.2. Reagents
For cell culture, recombinant human IL-21 was purchased from
Miltenyi Biotech. Recombinant human APRIL, recombinant human
BAFF, histidine-tagged soluble recombinant human CD40 ligand,
and an antipolyhistidine mAb were from R&D Systems
(Minneapolis, MN, USA). Phosphorothioate CpG-ODN 2006 was
purchased from Invivogen (San Diego, CA, USA) and Ara-C (cyto-
sine arabinoside) from Sigma–Aldrich.
For BCR stimulation, anti-human IgM afﬁnity puriﬁed goat
polyclonal Ab was purchased from R&D Systems (Minneapolis,
MN, USA).2.3. Receptor-blocking assay reagents
Anti-human APRIL (10 lg/ml), 10 lg/ml anti-human BCMA
(10 lg/ml), and anti-human TACI monoclonal Abs (mAbs; 10 lg/
ml) were purchased from R&D Systems (Minneapolis, MN, USA).
Functional-grade mouse IgG1j isotype and rat IgG2aj isotype con-
trols were purchased from eBioscience.
2.4. Flow cytometric analysis
To determine differentiation stages, the cells were reacted with
ﬂuorescein isothiocyanate (FITC)-anti-CD38 (eBioscience), PE-anti-
138, and APC-anti-CD19 mAbs (BD Biosciences, San Jose, CA, USA).
Dead cells were stained with propidium iodide (PI; Sigma–
Aldrich). To measure the expression levels of IgG on the surface of
naïve (CD27) B cells, cells were reacted with FITC-anti-IgG
(eBioscience). FITC-BCMA/TNFRSF17 antibodies from Novus
Biologicals (Littleton, Colorado, USA) and APC-anti-hTACI/
TNFRSF13B antibodies (R&D Systems) were used to measure APRIL
receptor expression on the surface of naïve (CD27) B cells. All ﬂow
cytometric analyseswere performedusing a FACS Calibur dual-laser
ﬂow cytometer using Cell Quest acquisition analysis software (BD
Biosciences).
2.5. Enzyme-linked immunosorbent assay
Ninety-six-well plates were coated with a polyclonal F(ab)2
goat anti-human IgG heavy chain Ab (Biosource, Camarillo, CA,
USA) or afﬁnipure F(ab0)2 goat anti-human IgM Fc5l fragment
speciﬁc Ab (Jackson Immunoresearch Laboratories, West Grove,
PA, USA) at 4 C overnight.
The plates were washed ﬁve times with phosphate-buffered
saline (PBS; Sigma–Aldrich) containing 0.1% Tween 20. A 100 ll
aliquot each of the supernatant from each culture step, media
alone, and IgG standards (to generate the calibration curve) were
diluted 1:200 to 1:10,000 and IgM standards (to generate the cali-
bration curve) were diluted from 1:1600 to 1:80,000 with PBS and
incubated in the wells over night at 4 C.
The plates were then washed ﬁve times with PBS containing
0.1% Tween 20 and incubated with horseradish peroxidase-
conjugated anti-human IgG or horseradish peroxidase-conjugated
anti-human IgM (Jackson Immunoresearch Laboratories, West
Grove, PA, USA) for 2 h at room temperature and then washed ﬁve
times with PBS containing 0.1% Tween 20.
After the addition of TMB substrate (Thermo Scientiﬁc,
Rockford, IL, USA), the optical density was measured at 630 nm
using a PowerScan4 Microplate Reader (DS Pharma Medical Co.),
and total IgG or IgM levels were determined from the calibration
curve.
2.6. BrdU cell proliferation assay
BrdU incorporation by naïve (CD27) B-cell-derived PCs was
quantiﬁed using a BrdU cell proliferation assay kit (Millipore,
Billerica, MA, USA). Naïve (CD27) B cells were cultured for 10,
14, 21, 28, and 56 days, and CD138+ PCs were collected at each
time. The BrdU enzyme-linked immunosorbent assay (ELISA) assay
was performed according to the manufacturer’s instructions. The
cells were pulsed with 20 ll of BrdU diluted 1:500 during the ﬁfth
day of culture. After adding BrdU, plates were centrifuged and cells
were denatured with FixDenat solution and then incubated for 1 h
at room temperature with 100 ll per well of diluted mouse anti-
BrdU mAb and washed three times with wash buffer diluted
1:50. After addition of 100 ll per well of goat antimouse IgG Ab-
peroxidase conjugate diluted 1:20,000 followed by incubation for
30 min at room temperature, the plates were washed three times.
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dase substrate was added and incubated for 30 min at room tem-
perature in the dark. The absorbance was measured at 630 nm
using a PowerScan4 Microplate Reader (DS Pharma Medical Co.).
The blank corresponded to 100 ll per well of culture medium with
BrdU, and the background corresponded to 100 ll per well of cells
plated in culture medium without BrdU.2.7. Quantitative real-time polymerase chain reaction
An miRNeasy Mini Kit (QIAGEN) was used to extract RNA from
cultured naïve (CD27) B cells on days 0, 7, 14, 21, 28, and 35. The
RNAs served as templates for cDNA synthesis using a high-capacity
cDNA synthesis kit (Applied Biosystems, CA, USA). The cDNA sam-
ples were ampliﬁed using a SYBR Premix Ex Taq Kit (Takara Bio,
Inc., Shiga, Japan). The primer sequences and conditions used for
quantitative real-time polymerase chain reaction (qRT-PCR) are
detailed in Supplementary Methods (1). A real-time reverse tran-
scription-PCR (RT-PCR) was performed using an MX3000P
(Agilent Technologies, Loveland, CO). Relative transcript levels
were calculated using the comparative CT method [26]. Gene
expression levels were normalized to those of the housekeeping
gene GAPDH.2.8. IgH chain V region mutation analysis
Total RNA was isolated from naïve (CD27) B cells on days 0 and
28, from memory (CD27+) B cells on day 0, and cDNA was synthe-
sized using random primers. Single-strand cDNA synthesis was
performed using a high capacity cDNA synthesis kit (Applied
Biosystems, CA, USA). IgH chain V (IGHV) regions were ampliﬁed
from cDNA using PrimeSTAR GXL DNA Polymerase (Takara Bio,
Inc., Shiga, Japan). VH-CH transcripts were ampliﬁed using the VH
forward primer and the CHl or CHc reverse primer. The primer
sequences and conditions used for qRT-PCR are detailed in
Supplementary Methods (2). Amplicons were gel puriﬁed, and
poly(dA) was added to their 30 ends using the Mighty TA-cloning
Reagent Set for PrimeSTAR (Takara Bio, Inc.) and were cloned using
a pGEM-T Easy TA Cloning Kit (Promega). PCR products were
sequenced using the BigDye Terminator Cycle Sequencing Kit
(Applied Biosystems) and analyzed using an Applied Biosystems
Prism 310 Genetic Analyzer.2.9. Statistical analysis
The data are expressed as median values and ranges. The sig-
niﬁcance of differences between variables was evaluated using a
paired or unpaired Student t test with SPSS Statistics 20 software
(IBM Corporation, Armonk, NY). A two-tailed P value < 0.05 was
considered statistically signiﬁcant.3. Results
3.1. Absence of IGHV somatic hypermutation in pooled CD27 B cells
collected from healthy human donors
We separated naïve (CD27) B-cell-enriched populations from
total peripheral blood B cells using negative selection. These cells
did not show patterns of IGHV somatic hypermutation similar to
those of classical memory B cells. In contrast, memory (CD27+) B
cells showed patterns of IGHV somatic hypermutation (Fig. 1).3.2. APRIL supports longer survival of naïve (CD27) B-cell-derived PCs
in vitro and increases IgG secretion compared with BAFF
We compared the effects of BAFF and APRIL on naïve (CD27) B
cells in vitro. In the presence of exogenous BAFF, there were signiﬁ-
cant differences in the differentiation rate of PCs (35.6 ± 5.2% vs
4.2 ± 2.7%) on day 14 and (21.3 ± 5.9% vs 2.2 ± 1.8%) on day 25
between cells treated with BAFF and the controls (P < 0.01,
P < 0.01, respectively; Fig. 2A), but there were no signiﬁcant differ-
ences (3.3 ± 2.1% vs 2.0 ± 0.4%) on day 7, (4.3 ± 2.9% vs 2.2 ± 1.8%)
on day 35 (Fig. 2A). IgG concentrations increased signiﬁcantly in
supernatants of cultures treated with BAFF compared with those
of controls on day 14 (P < 0.01), on day 25 (P < 0.05), on day 35
(P < 0.05) (Fig. 2B). APRIL increased the differentiation rate, and
there were signiﬁcant differences (24.7 ± 9% vs 1.3 ± 2.8%) on day
25 and (19.6 ± 4.6% vs 2.2 ± 1.8%) on day 35 between cells treated
with APRIL and the controls (P < 0.01, P < 0.01, respectively;
Fig. 2A). Moreover, the production of IgG by cells treated with
APRIL was signiﬁcantly higher compared with controls on days
25 and 35 (P < 0.05, P < 0.001, respectively; Fig. 2B).
3.3. APRIL promotes the differentiation of naïve (CD27) B cells
derived from B-cell-derived plasmablasts into mature PCs
APRIL maintained the number of naïve (CD27) B-cell-derived
PCs on days 21 (P < 0.05) and 28 (P < 0.01) compared with the con-
trols (Fig. 3A). To ensure that the progeny PCs were derived from
naïve (CD27) B cells on day 28, mRNA was isolated from total B
cells on day 28, and analysis of IGHV mutations was performed.
IGHV somatic hypermutation was not detected (Fig. 3B).
We next determined the effect of APRIL on naïve (CD27) B cells
during each stage of differentiation. Fluorescence-activated cell
sorting (FACS) analysis shows that the plasmablast (PB) dif-
ferentiation rate (56.6 ± 3.3%) of controls was signiﬁcantly
increased compared with cells treated with APRIL (31.9 ± 1.7%)
on day 25 (P < 0.001; Fig. 3C). However, we did not detect the dif-
ferentiation of PCs in control cultures compared with cultures trea-
ted with APRIL on day 25 (Fig. 2A). In addition, we estimated the
effect of APRIL on more mature PCs. When naïve (CD27-) B cells
were treated with an anti-human APRIL mAb on day 21, there
was no signiﬁcant differences on the rate of differentiation of naïve
(CD27) B-cell derived PCs between Ab-treated cells (75.9 ± 7.6%)
and controls (72.9 ± 4.4%) on day 35 (Fig. 3D).
To determine why naïve (CD27) B cell appeared to be dif-
ferentiated into more mature PCs, we gated on PCs on days 14,
21, 28, and 56 and then evaluated cell-surface expression of
CD138 on naïve (CD27) B-cell-derived PCs compared with that
of PBs. We found that the PCs expressed signiﬁcantly higher levels
of CD138 compared with those of PBs, and the expression of CD138
on the PC surface was increased in the presence of APRIL (Fig. 3E).
3.4. Naïve (CD27) B-cell class-switching and induction of terminal
differentiation by APRIL
Next, we determined the stage of differentiation when naïve
(CD27) B cells underwent Ig class switching. All naïve (CD27) B
cells were stained with FITC-anti IgG on days 1, 4, 7, and 14. The
upregulation of IgG on the surface of naïve (CD27) B cells in the
presence or absence of exogenous APRIL was detected on days 1,
4, and 7 (all P > 0.5). In contrast, IgG levels increased in the pres-
ence of APRIL compared with those of control cells on day 14
(P < 0.01; Fig. 4A).
We next investigated the effect of stimulating the BCR on the
differentiation of naïve (CD27) B cells. Stimulating the BCR signiﬁ-
cantly promoted Ig class switching of naïve (CD27) B cells on days
1, 4, 7, and 14 compared with the controls (P < 0.01, P < 0.001,
Fig. 1. Analysis of mutations in sequences encoding the IGHV. Total RNA was isolated from naïve (CD27) and memory (CD27+) B cells on day 0. VH5/6 rearrangements in
memory (CD27+) B cell (A) and naïve (CD27) B cell (B) subsets. (A) VH5/6 was rearranged in cells preparations enriched in memory (CD27+) B cells. (B) Somatic
hypermutation of the IGHV region of VH5/6 was not detected in preparations enriched in naïve (CD27) B cells. IGHV rearrangement junctions are indicated with a solid
triangle. Naïve (CD27) and memory (CD27+) B cells were collected from ﬁve independent healthy donors, and the data represent ﬁve independent experiments.
Fig. 2. The effects of BAFF and APRIL on the differentiation of naïve (CD27) B cells. (A) Naïve (CD27) B cells were cultured and stained with ﬂuorescein isothiocyanate-anti-
CD38, phycoerythrin-anti-CD138, and APC-anti-CD19 mAbs on days 7, 14, 25 and 35. Fluorescence-activated cell sorting analysis of the expression of CD19, CD38, and CD138
in vitro by naïve (CD27) B cells isolated from the same donor. PCs were identiﬁed as CD19+CD38++CD138+. (B) IgG production in the culture supernatants of cells treated or
not with APRIL or BAFF on days 7, 14, 25, and 35. Naïve (CD27) B cells were collected from 10 healthy donors, and the data represent 10 independent experiments. The
graphs show the mean ± standard error of the mean (SED). The statistical signiﬁcance of the differences was evaluated using a paired t test. Signiﬁcant changes from baseline
are indicated with an asterisk (⁄P < 0.05, ⁄⁄P < 0.01).
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(CD27) B cells were cultured with the APRIL addition in the pres-
ence or absence of BCR stimulation. FACS analysis revealed signiﬁ-
cant differences in the percentages of PBs between BCR-stimulated
(day 7, 92.5 ± 2.2%; day 14, 86.7 ± 3.4%; day 25, 60.1 ± 5.5%) and
BCR-unstimulated cells (day 7, 12.8 ± 1.2%; day 14, 26.0 ± 5.9%;
day 25, 31.8 ± 2.1%) on days 7, 14, and 25 (P < 0.0001, P < 0.0001,
P < 0.0001, respectively; Fig. 4B). In contrast, BCR stimulation did
not promote the differentiation of naïve (CD27) B cells into PCs
compared with BCR-unstimulated on days 7, 14, and 25 (Fig. 4B).
Further, IgG levels in culture supernatants of BCR-stimulated cells
were signiﬁcantly higher compared with those on day 14(P < 0.05), although there were no signiﬁcant differences
between BCR-stimulated and BCR-unstimulated cells on day 25
(Fig. 4C).
Next, we assessed the ability of naïve (CD27) B-cell-derived
PCs to synthesize DNA to determine whether naïve (CD27) B-
cell-derived PCs were terminally differentiated by using a BrdU
ELISA assay. We found a decreasing linear rate of absorbance per
PC count from day 10 that changed little between days 21 and
56 (Fig. 5A), suggesting that naïve (CD27) B-cell-derived PCs lost
the ability to synthesize DNA up to day 21. When we added Ara-C
to the culture medium on day 21 and used FACS to analyze cell
proliferation and survival on days 28 and 56, we found that only
Fig. 3. The effect of APRIL on the differentiation of naïve B cells. (A) PC counts of cultures treated or not with APRIL. (B) To ensure that all PCs were derived from naïve (CD27)
B cells, on day 28 we did not detect somatic IGHV hypermutation of VH5/6. IGHV rearrangement junctions are indicated with a solid triangle. (C) Fluorescence-activated cell
sorting analysis of the expression of CD19, CD38, and CD138 in vitro by naïve (CD27) B cells isolated from the same donor. PBs were identiﬁed as CD19+CD38++CD138,
activated B cells as CD19+CD38+CD138. (D) Naïve (CD27) B cells were cultured in the presence of APRIL for 21 days and then cultured with the addition of APRIL for
additional 14 days in the presence or absence of an anti-APRIL antibody and all these cells were analyzed by FACS on day 35. (E) We estimated CD138 levels on the surface of
naïve (CD27) B-cell-derived PBs on day 14 and those of naïve (CD27) B-cell-derived PCs on days 14, 21, 28, and 56. CD138 expression by PCs was signiﬁcantly increased.
Histograms show CD138 expression monitored on days 14, 21, 28, and 56 (median value; mean ± SED). Naïve (CD27) B cells were collected from ﬁve healthy donors, and the
data represent ﬁve independent experiments. The statistical signiﬁcance of the differences was evaluated using a paired t test. Signiﬁcant changes from baseline are indicated
with an asterisk (⁄P < 0.05, ⁄⁄P < 0.01).
Fig. 4. Analysis of Ig class switching to estimate the effect of B-cell receptor (BCR) stimulation on the differentiation of naïve (CD27) B cells. Naïve (CD27) B cells were
cultured and stained with a ﬂuorescein isothiocyanate-conjugated anti-IgG antibody on days 1, 4, 7, and 14. We compared cell-surface IgG levels of naïve (CD27) B cells
treated with APRIL or not. These results indicate that APRIL exerted a signiﬁcant effect on naïve (CD27) B-cell class switching compared with the controls on day 14
(P < 0.01). (A) Histograms showing expression of IgG determined on days 1, 4, 7, and 14 (median value; mean ± SED. BCR stimulation signiﬁcantly altered naïve (CD27) B-cell
class switching compared with controls on days 1, 4, 7, and 14 (P < 0.01, P < 0.001, P < 0.001 and P < 0.0001, respectively), and (B) ﬂuorescence-activated cell sorting analysis
revealed that BCR stimulation promoted the differentiation of naïve (CD27) B cells into PBs. (C) Comparison of IgG levels in culture supernatants of treated and untreated
cells on days 7, 14, and 25. Naïve (CD27) B cells were collected from 10 healthy donors, and the data represent 10 independent experiments. The statistical signiﬁcance of the
differences was evaluated using a paired t test. Signiﬁcant changes from baseline are indicated with an asterisk (⁄P < 0.05).
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and activated B cells did not survive in the presence of Ara-C on
day 28 (Fig. 5B). The numbers of PBs in the control cultures on
day 28 were increased signiﬁcantly compared with culturestreated with Ara-C (P < 0.0001), but there were no signiﬁcant dif-
ferences on the numbers of PCs (Fig. 5C), and the IgG levels in con-
trol culture supernatants were increased signiﬁcantly compared
with cultures treated with Ara-C on day 28 (Fig. 5D; P < 0.01). On
Fig. 5. DNA synthesis by naïve (CD27) B-cell-derived PCs. (A) We cultured naïve (CD27) B cells for 10, 14, 21, 28, and 56 days and separated only CD138+ PCs. All PCs were
cultured in the presence of BrdU on the ﬁfth day. These results represent experiments using cells pooled from ﬁve independent healthy donors. Ara-C (20 lg/ml) was added to
cultures of naïve (CD27) B cells after 21 days. On days 28 and 56, cells were subjected to ﬂuorescence-activated cell sorting analysis. We compared the phenotypes of cells
treated or not with Ara-C. (B) Representative analyses of CD19, CD38, and CD138 expression of cells from the same donor on days 28 and 56. Viable PCs expressed
CD19+CD38+CD138+, PBs expressed CD19+CD38++CD138, and activated B cells expressed CD19+CD38+CD138. (C) The numbers of PBs and PCs were determined on day 28 in
cultures treated or not with Ara-C on day 21 and the numbers of PCs was also determined on day 21 in cultures treated or not with Ara-C on day 14. In addition, IgG levels (D)
were determined on day 28 in cultures treated or not with AraC on day 21. (E) We estimated antibody (Ab) production per naïve (CD27) B-cell-derived PC per day. Naïve
(CD27) B cells were cultured for 28 and 56 days, and we replenished the medium and cultured them for 1 day to calculate the IgG production per day. We calculated this
value by dividing the amount of IgG in the culture supernatant by the number of viable PCs at the time of collection of the culture supernatant. Cultures were treated or not
with Ara-C, and we compared Ab production per naïve (CD27) B-cell-derived PC per day on days 28 and 56 between the Ara-C-treated (*) and untreated cultures. Ara-C did
not affect IgG levels on days 28 and 56 compared with controls. Naïve (CD27) B cells were collected from 10 healthy donors, and data are representative of 10 independent
experiments. The statistical signiﬁcance of the differences was evaluated using a paired t test. Signiﬁcant changes from baseline are indicated with an asterisk (⁄P < 0.05,
⁄⁄P < 0.01, ⁄⁄⁄P < 0.001).
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numbers of PCs on day 21 to compared with the control group
when it was administered on day 14 (P < 0.05; Fig. 5C).
We next compared IgG production per naïve (CD27) B-cell-
derived PCs and per day in untreated cultures treated with those
treated with Ara-C. To calculate the rate of IgG production per
naïve (CD27) B-cell-derived PC and per day, we replenished the
culture medium and cultured the cells for 1 day. The values were
calculated by dividing the amount of IgG in the culture supernatant
by the number of viable PCs at the time of collection of the culture
supernatant. We found that when Ara-C was added on day 21,
there were no detectable differences in IgG levels on days 28 and
56 compared with the controls (Fig. 5E). When we replenished
the culture medium and analyzed the culture supernatant by
ELISA, these cultured cells were analyzed by FACS on day 7, 14,
21 and when we added Ara-C to the culture medium, we collected
all these cells to analyze them, the details of which are shown in
Supplementary scheme (1).
3.5. APRIL-induced terminal differentiation of naïve B-cell-derived PCs
correlates with increased levels of PRDM1 and XBP1 mRNAs
When we examined the gene expression proﬁle of naïve
(CD27) B cells, we found that the levels of PAX5 and BCL6mRNAs decreased (Fig. 6A and B), while those of PRDM1 and
XBP1 increased (Fig. 6C and D).
3.6. APRIL induces the differentiation of naïve B cells to PCs via BCMA
and TACI
Using FACS, we estimated the levels of BCMA and TACI
expressed by naïve (CD27) B cells on days 7, 14, and 21 and found
that BCMA levels increased from days 7 to 14 in the absence of
exogenous APRIL with little change on day 21. TACI levels
increased from days 7 to 14 in the absence of exogenous APRIL
and then returned to their initial levels on day 21 when germinal
center B cells (GCBCs) differentiated into PCs (Fig. 7A).
When we used a neutralizing Ab to block APRIL binding, BCMA
had no detectable effect on the rate of proliferations of naïve
(CD27) B-cell-derived PCs on day 25 when the Ab was adminis-
tered on days 1 and 7 (Fig. 7B). However, administration of
antibodies against either BCMA or APRIL on day 14 inhibited dif-
ferentiation into PCs on day 25 (Fig. 7C). IgG and IgM levels in cul-
ture supernatants were signiﬁcantly decreased compared with
those of controls on day 25 when the Ab was administered on
day 14 (P < 0.05, P < 0.05, respectively; Fig. 7D).
FACS analysis revealed signiﬁcant differences in the percent-
ages of PBs on day 25 between antibodies against BCMA-treated
Fig. 6. Expression of genes encoding transcription factors involved in the differentiation of naïve (CD27) B cells into PCs. Naïve (CD27) B cells were cultured with APRIL for
0, 10, 25, and 35 days, and then the levels of BCL6, PAX5, XBP1, and PRDM1 mRNAs were evaluated using quantitative real-time polymerase chain reaction (A, B, C, D). Naïve
(CD27) B cells were collected from 10 independent healthy donors, and the data are representative of 10 independent experiments.
Y. Matsuda et al. / Cellular Immunology 295 (2015) 127–136 133on day 14 and control cells (92.6 ± 1.5% vs 31.8 ± 2.1%; P < 0.0001),
but naïve (CD27) B cells could not differentiate into PCs
(5.2 ± 0.6%) to compare with control cells on day 25 (31.9 ± 1.7%)
(Fig. 7E).
Moreover, when a neutralizing Ab against TACI was added to
cultures on day 14, PC counts on day 25 were unchanged (Fig. 7B
and C). When TACI-neutralizing antibodies were added to cultures
on day 14, IgM production was increased signiﬁcantly (P < 0.0001),
and IgG production was decreased signiﬁcantly (P < 0.05) com-
pared with controls on day 25 (Fig. 7D).4. Discussion
Human memory B cells differentiate into long-lived PCs in vitro
[24]. In contrast, Huggins et al. [23] differentiated human naïve
(CD27) B cells into CD138+ PCs but did not show that these cells
differentiated into long-lived PCs in vitro. Therefore, we attempted
to induce human naïve (CD27) B cells to differentiate into long-
lived PCs in vitro. Peripheral blood B cells consist of naïve and
memory B cells, and they can be isolated because the latter express
CD27 [27,28]. However, memory B cells may not express CD27,
and their patterns of IGHV somatic hypermutation are similar to
those of classical CD27+ memory B cells [28]. In the present study,
we did not detect IGHV somatic hypermutations in peripheral
blood cells enriched for naïve (CD27) B cells on day 0, unlike
memory (CD27+) B cells. Further, after culture for 28 days, we
found that the PCs on day 28 were indeed derived from naïve
(CD27) B cells, because the surviving B cells did not express
mutated rearranged IG genes. Therefore, we suggest that selection
based on the lack of detection of CD27 was sufﬁcient to ensure that
the differentiation of naïve B cells could be monitored using analy-
sis of IGHV mutations.
We examined the effects of the TNF family members BAFF and
APRIL in our culture system. The receptors that bind to APRIL, BAFF,
or both include the BAFF receptor (BAFF-R), TACI, and BCMA.
Mature B cells express BAFF-R, which binds BAFF but not APRIL.In contrast, TACI and BCMA bind BAFF and APRIL. TACI is expressed
strongly by GCBCs, whereas BCMA is expressed mostly by PCs.
APRIL and BAFF bind to TACI with equal afﬁnity, and APRIL binds
BCMA with higher afﬁnity than BAFF [28–35]. Bone marrow PCs
from Bcm-knockout mice have a lower survival rate compared with
those from wild-type mice, indicating that signal transduction
through BCMA is related to the long-term survival of PCs
[3,11,36]. The pattern of temporal expression of BAFF suggests that
it acts during earlier stages of B-cell differentiation than APRIL. For
example, when mouse B cells are cultured on BAFF-feeder cells,
they differentiate into memory B-like cells. However, these cells
must be transferred into mice to differentiate into long-lived PCs
[37].
In our study, addition of BAFF promoted naïve (CD27) B cells
differentiation into immature PCs that did not exhibit long-term
survival; however we did not conﬁrm these cells further dif-
ferentiation into more mature PCs in vitro compared with cells
treated with APRIL.
Here, we show the addition of recombinant APRIL to the med-
ium, maintained cultures of naïve (CD27) B-cell-derived PCs for
56 days. First, we demonstrated upregulated expression of the sur-
face antigen CD138 and increased secretion of IgG by the B cells as
differentiation progressed. This is consistent with evidence show-
ing that CD138 expression increases gradually as PCs mature
[24,38,39]. Additionally, we observed the effect of APRIL on each
differentiation stage of naïve (CD27) B cell in vitro. With respect
to IgG class switching, naïve (CD27) B-cell-derived PCs usually
secreted IgM [40]. Therefore, we estimated how APRIL inﬂuenced
switching from IgM to IgG by naïve (CD27) B cells in our culture
system. We detected increased expression of cell-surface IgG by
naïve (CD27) B cells in cultures treated with APRIL or not, indicat-
ing the switch from IgM to IgG production on days 1, 4, and 7. It has
been already reported that IL-21, CD40L and CpG-ODN, which were
added to the B-cell culture medium, induce IgG class switching
[41–43]. Therefore, we expected that any of these cytokines would
support class switching by naïve (CD27) B cells on days 1, 4, and
7. However, APRIL signiﬁcantly promoted naïve (CD27) class
Fig. 7. Effects of antibodies against APRIL receptors on the phenotype of naïve (CD27) B cells. (A) We performed ﬂuorescence-activated cell sorting (FACS) analyses to
estimate the levels of cell-surface B-cell mature antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) expressed by
naïve (CD27) B cells on days 7, 14, and 21. BCMA expression increased up to day 14 and was changed little on day 21. TACI levels increased up to day 14 and then decreased
to their initial levels. (B) We added an anti-APRIL mAb and an anti-APRIL receptor mAb or mouse IgG1j on days 0 and 7 and then determined the number of naïve (CD27) B-
cell-derived PCs on day 25. (C) Number of viable PCs on day 25 after treatment on day 14. (D) On day 25, we estimated IgG and IgM levels in cultures treated or not with an
anti-APRIL receptor mAb on day 14. (E) FACS analysis shows that the anti-BCMA antibody altered cell differentiation on day 25. Naïve (CD27) B cells were collected from 10
healthy donors, and the data represent 10 independent experiments. The graphs show the mean ± SED. Signiﬁcance was tested using a paired t test. Signiﬁcant changes from
baseline are indicated by an asterisk (⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001).
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time points. From the above, APRIL supported naïve (CD27) B cell
IgG class switching and differentiation into a more mature PC phe-
notype [43,44].
When we analyzed the expression of mRNAs speciﬁcally
expressed by PCs, we found that the levels of BCL6 and PAX5
mRNAs were downregulated and those of PRDM1 and XBP1 were
upregulated [16,21,23,45–52]. These ﬁndings support the conclu-
sion that APRIL induced the differentiation of naïve (CD27) B cell
into PCs.
However, the longevity of naïve (CD27) B-cell-derived PCs and
calling them long-lived PCs are still questionable, because only
indirect evidence is available on the longevity of PCs [53,54]; that
is, the differences in survival of PCs have important implications
for sustaining host immunity. In the absence of exogenous APRIL,
naïve (CD27) B-cell-derived PCs survived for approximately
14 days in our cell culture system. Therefore, it is possible that
naïve (CD27) B cells differentiated into PCs after day 14, persisted
until day 28 and then died rapidly. Therefore, the fate of PCs that
were treated with Ara-C on day 21 must be addressed, because
long-lived PCs survived as postmitotic cells [55–57]. Thus, we cul-
tured naïve (CD27) B cells in the presence of the proliferation
inhibitor Ara-C, which is used as an anticancer drug that inhibits
cell proliferation by inducing DNA damage and apoptosis [58].
We found that only viable postmitotic PCs were present on days
28 and 56, and that there were no signiﬁcant differences in IgG
production of individual PCs between days 28 and 56.From the above, naive (CD27) B cell-derived PC lost the ability
to synthesize DNA by day 21 in the presence of APRIL, and IgG pro-
duction of individual postmitotic PCs was completed by day 28.
The culture method described here is extremely simple,
because it only involves the addition of APRIL, IL-21, CD40 ligands,
and CpG-ODN and does not require unknown cytokines or interac-
tions between B cells and stromal cells despite reports that
together, APRIL, IL-6, and other factors maintain the viability of
bone marrow-derived PCs or PCs generated in vitro, including PCs
derived from memory B cells [29,30]. Further, memory B cells dif-
ferentiate into long-lived PCs when cultured in the presence of
supernatants from the bone marrow-derived stromal cell line
M2-10B4 [24], which supports long-term culture of human bone
marrow stem cells. How M2-10B4 cells contribute to the survival
of PCs is unknown, but memory B cells may require well-balanced
support from stromal cells [31,59–61].
Cocco et al. [24] differentiated memory B cells into long-lived
PCs by stimulating the BCR. Therefore, we investigated the effect
of BCR stimulation on the proliferation and differentiation of naïve
(CD27) B cells in vitro. We showed here that BCR stimulation
induced naïve (CD27) B cells to undergo IgG class switching and
to proliferate and differentiate into PBs but did not support dif-
ferentiation of these cells into PCs in vitro (Supplementary Fig. 1).
In addition, APRIL could support differentiation of naïve (CD27)
B cells into PCs under normal circumstances; however, it was not
affected by the addition of BCR stimulation. BCR stimulation pro-
moted naïve (CD27) B cell proliferation; therefore, we assumed
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in vitro (Fig. 4B).
From the above mentioned, our study suggested that BCR stim-
ulation was effective for naïve (CD27) B cells proliferation and
class switching; however, we did not conﬁrm that it affects the
growth and survival of PCs in vitro, as it has been reported that
BCR stimulation affects B cell selection or growth before B cells
migrate to the bone marrow in vivo [62–64].
We show further that neutralizing antibodies against the APRIL
receptor BCMA, which was upregulated on day 14 (Fig. 6D), inﬂu-
enced the differentiation of naïve (CD27) B cells into PCs on day
25 (Fig. 7F). Moreover, when the anti-human APRIL mAb was admi-
nistered on day 21, it did not affect the survival of PCs on day 35.
These results suggest that through BCMA, APRIL is required for the
differentiation of PBs into more matured PCs but these PCs could
survive without the APRIL addition after acquiring long-lived
phenotype.
We found as well that the number of naïve (CD27) B-cell-
derived PCs on day 25 was not altered by the addition of a neu-
tralizing Ab against TACI despite the upregulation of TACI on day
14. However, IgM production on day 25 was increased signiﬁcantly
when cells were incubated with a neutralizing Ab against TACI on
day 14 compared with controls, and that the production of IgG sub-
classes was suppressed on day 25. These ﬁndings are consistent
with the requirement for TACI for IgG production by B-cell cultures
derived from Taci-knockout mice [65–67]. In that splenic B-cell
culture system, APRIL or BAFF cooperates with Toll-like receptor-
9 agonists to induce B-cell differentiation, which is blocked by a
neutralizing Ab against TACI [35].5. Conclusion
Our results lead us to conclude that APRIL plays an important
role in human naïve (CD27) B cells class switching through TACI
and the differentiation of human naïve (CD27) B-cell derived
PBs into more mature PCs through BCMA in vitro.
Additionally, naïve B (CD27) cells could survive without the
APRIL supplementation in vitro after acquiring long-lived
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